drugset / Trial / NCT06590051
AMG 335 Expanded Access Program for IgG4-Related Disease
Summary
Expanded access requests for AMG 335 may be considered for adult patients with a confirmed diagnosis of IgG4-related disease. To request access, use Responsible Party contact information provided in this record.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Inebilizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.